Get 40% Off
🚀 Our AI Picked 6 Stocks that Jumped +25% in Q1. Which Picks Will Soar in Q2?Unlock full list

Japan's Astellas Pharma to buy Iveric Bio for $5.9 billion

Published 05/01/2023, 04:53 AM
Updated 05/01/2023, 05:04 AM
© Reuters.  Japan's Astellas Pharma to buy Iveric Bio (ISEE) for $5.9 billion

Astellas Pharma (OTC:ALPMY) announced today a deal to merge its Berry Merger unit with Iveric Bio (NASDAQ:ISEE) in a deal valued at $5.9 billion.

The agreement is based on the price of $40 for each ISEE share in cash, a 64% premium to Iveric Bio's unaffected closing share price of US$24.33 on March 31, 2023.

"We are pleased to reach an agreement with Iveric Bio, a company with exceptional expertise in the R&D of innovative therapeutics in the ophthalmology field," said Naoki Okamura, president and CEO, Astellas.

The two companies expect the transaction will be closed in the second quarter of Astellas' fiscal year 2023 (third calendar quarter of 2023).

"This transaction with Astellas, a highly respected pharmaceutical company, demonstrates the significant value that we have built for our stockholders and recognizes the tremendous work by our dedicated team at Iveric Bio," said Glenn P. Sblendorio, chief executive officer of Iveric Bio.

Stifel analysts said Astellas is acquiring “a successful GA program and the ability to shape a commercial effort.”

“Astellas was not the most obvious partner given some of the larger players in retinal disease. Regardless, given Astellas’ strategic goals, we expect this to be a strong fit and applaud ISEE ability to complete this program while finding a partner committed to its retinal platform,” the analysts said in a note.

Iveric shares are indicated at $38.75 in pre-open Monday, up almost 18% on the day.

 
 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.